This is a preview of subscription content, log in via an institution to check access.
References
Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S et al. Polymerase chain reaction detection of the BCR–ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632–2638.
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.
Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.
Merx K, Muller MC, Kreil S, Lahaye T, Hehlmann R, Hochhaus A . Early reduction of BCR–ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16: 1579–1583.
Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004; 103: 2284–2290.
Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica 2004; 89: 49–57.
Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV . The presence of BCR–ABL fusion genes in leukocytes of normal individuals: implications for the assessment of minimal residual disease. Blood 1998; 92: 3362–3367.
Scheuring UJ, Pfeifer H, Wassmann B, Bruck P, Gehrke B, Petershofen EK et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr–Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (ST1571). Blood 2003; 101: 85–90.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lange, T., Bumm, T., Mueller, M. et al. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia 19, 1262–1265 (2005). https://doi.org/10.1038/sj.leu.2403752
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403752
- Springer Nature Limited
This article is cited by
-
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
Leukemia (2010)
-
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
Leukemia (2007)